Addictive Disorders & Addiction Therapy

Dr. Felix-Martin Werner studied human medicine at the university of Bonn. He has been working as a medical teacher in the formation of geriatric nurses, occupational therapists and assistents of the medical doctor at the Euro Academy in Pößneck since 1999. He has been doing scientific work at the Institute of Neurosciences of Castilla and León (INCYL) in Salamanca (Spain) since 2002. With Prof. Rafael Coveñas, he assisted at over 30 national and 12 international congresses of neurology and published over 40 reviews about neural networks in neurological and psychiatric diseases. Since 2014, Dr. Werner has belonged to the editorial board of the Journal of Cytology & Histology.

Neurology and psychiatry or psycho-and Neuropharmacology

Simon Raymond is a Consultant (medicine and surgery) specialising in Medical and Scientific Research and an Alumnus of Melbourne University (Rank of Number 1 in Australia and Number 33 in the World). The above stated Researcher has acted as a Reviewer for the respected Medical Journal of Australia, has received invitations internationally to review from prestigious medical journals including Journal of American Medical Association Network. He has received award in recognition of his research by Royal Australasian College of Surgeons (PSC, 2006) and invited to conferences internationally as an official Delegate and Researcher, including that in USA and China. Dr Simon Raymond is a graduate of medical school who shifted from clinical practitioner medicine and surgery into a focus on high level scientific research. Dr Simon Raymond has acted as the Principle Researcher in the highest-powered form of medical trial—Randomised Controlled Trial (RCT). The above stated Researcher is also a Member of the Golden Key International Society for Honoured and outstanding Academics and has been cited as a Notable Global Leader. Dr Simon Raymond’s research has been indexed by well respected universities including Cornell University

Axis, Copying Neurology, IP, Offences, Thef

Raffaele Pilla, Pharm.D., Ph.D., Doctor Europaeus, received his Master’s degree in Pharmacy at G. d’Annunzio University in Chieti-Pescara, Italy in 2005, where he also served internships at the Cell Physiology Laboratory and Molecular Biology Laboratory. Prior, he was an Erasmus Student at Faculté de Pharmacie de Reims in Reims, France. He received his Doctor Europaeus in 2010 from Pitié-Salpétrière Institute in Paris, France. Also in 2010, he received his Ph.D. in Biochemistry, Physiology, and Pathology of Muscle at G. d’Annunzio University in Chieti-Pescara, Italy. He was hired as a Postdoctoral Scholar in the Department of Pharmacology and Physiology at the University of South Florida in Tampa, on two research grants funded by the Office of Naval Research (US Navy) and Divers’ Alert Network. He has written and lectured widely worldwide. He has been involved in on-going research at the University of South Florida with the use of ketone esters.

Epileptic seizures and Brain cancer, Ketogenic diets, Oxygen toxicity, Physiology, Ketone Esters adopted in the metabolic treatment of epilepsy and cancer, Ketogenic Diet administered in patients affected by epilepsy and cancer.

Marco Carotenuto graduated from Università degli Studi della Campania Luigi Vanvitelli. He is Senior Researcher from 2011 to November 2017in Child and Adolescent Neuropsychiatry at the Università degli Studi della Campania Luigi Vanvitell. In December 2017 he was appointed as the Associate Professor of Child and Adolescent Neuropsychiatry at the Università degli Studi della Campania Luigi Vanvitell. He was awarded with Best scientific contribution oral presentations from X Congress Italian Society of Orthopedics And Medicine, Florence, Best Oral Communication Award from Napule é Congress and he is one of the Honorary member of the New Medical School Salernitana. He had published totally 114 articles in reputed journals.

Epilepsy, Idiopathic generalized epilepsy, Childhood absence epilepsy, EEG, Sleep, Memory and Learning, Electroencephalography, Neurological Diseases, Clinical Neurology, Neuroimaging, Neurophysiology.

Dagmar Amtmann is a psychologist and UW research associate professor with the Department of Rehabilitation Medicine. Dr. Amtmann's research interests include improving measures of patient reported outcomes such as pain, fatigue, and participation using modern measurement theories; statistical analytic approaches using multilevel and latent variable modelling; and instructional, information, and assistive technology for individuals with cognitive disabilities (with a particular focus on reading and writing technology for both children and adults).

Improving measures of patient reported outcomes such as pain, fatigue, and participation using modern measurement theories; statistical analytic approaches using multilevel and latent variable modelling; and instructional, information, and assistive technology for individuals with cognitive disabilities.

Joseph I. Sirven, M.D., is a professor of neurology and editor-in-chief of Epilepsy.com. He is currently chair of the AAN Education Meeting Subcommittee and he is on the board of directors for the American Brain Foundation and the editorial board of Neurology Now. Previously, he served as director of education for Mayo Clinic's Arizona campus with oversight over all educational activities at the Arizona campus, including medical student rotations, residencies, fellowships, Ph.D. candidates, nursing, allied health and continuing medical education programs. He was the previous chair of Neurology at Mayo Clinic's campus is Arizona and the previous vice chair of the Epilepsy Section of the American Academy of Neurology, chair of the Communication Council for the American Epilepsy Society and former chair of the Professional Advisory Board for the Epilepsy Foundation.

Epilepsy and seizure treatments in adults and children (particularly older adults) Epilepsy surgery Electroencephalography Investigational anti-epilepsy drugs Status epilepticus Vagal nerve stimulator Ketogenic diet.

Intractable seizures plague approximately a third of epilepsy patients. Despite their prevalence, the mechanisms underlying intractable seizures remain unclear and difficult to study. One factor clouding our understanding of seizure intractability stems from existing animal models of epilepsy, which have not specifically modeled intractable seizures or genetic disorders that often associate with intractable seizures, like Focal Cortical Dysplasia (FCD) or Tuberous Sclerosis Complex (TSC). New animal models are greatly needed to understand the underlying causes of intractable seizures and develop new therapies aimed at these indications. Using in utero electroporation to transfect a small population of neurons in vivo with constitutively active mutant of Ras homolog enriched in brain (RhebCA), we have successfully developed a new mouse model of spontaneous epilepsy based on the genetic etiology of mTOR-o-pathies. This model recapitulates both anatomical and behavioral phenotypes of human TSC and FCD. RhebCA transfected animals develop focal cortical malformations that contain dysplastic neurons, cortical dyslamination and white matter heterotopia. Seizures also spontaneously develop as early as postnatal day18, and persist throughout entire lifespan of the animals (2 years). Seizures are the only complication these animals have, otherwise they are completely healthy, making them ideal subjects to study mechanistic causes of seizures and seizure-dependent downstream behavioral and physiological effects. With this model, we have elucidated several mechanisms that contribute to seizure-genesis in TSC and FCD. Lastly, we also use this model to develop new therapies, including novel cannabinoids and RNA interference approaches to mitigate refractory seizures

Neuroscience , Neurosurgery

Dr. Denis Larrivee is a Visiting Scholar at the Mind and Brain Institute, University of Navarra Medical School and Loyola University Chicago and has held professorships at the Weill Cornell University Medical College, NYC, and Purdue University, Indiana. A former fellow at Yale University's Medical School he received the Association for Research in Vision and Ophthalmology's first place award for studies on photoreceptor degenerative and developmental mechanisms. He is the editor of a recently released text on Brain Computer Interfacing with InTech Publishing and an editorial board member of the journals Annals of Neurology and Neurological Sciences (USA) and EC Neurology (UK). An International Neuroethics Society Expert he is the author of more than 80 papers and book chapters in such varied journals/venues as Neurology and Neurological Sciences (USA), Journal of Neuroscience, Journal of Religion and Mental Health, and IEEE Explore. In 2018 he was a finalist in the international Joseph Ratzinger Expanded Reason award.

Neurobiology, Neuroscience, Neurology, Psychiatry, Ophthalmology, Cognitive Neuroscience, Neuroimaging, Cognitive Neuropsychology, Ethics.

Specialist for Spinal surgery, Head and cerebral neurosurgery, Neurosurgical Spine Surgery in Berlin

Spinal surgery, Head and cerebral neurosurgery, Neurosurgical Spine Surgery

Dario Furnari is Ph.d. in Applied Biomedical Sciences in the neuroscience and traumatology and neuropharmacology sector

Anatomy, psycology, Traumatology

Dr Jacqueline Delfgaauw is Executive Director, Clinical Science. Experience in the clinical development of various products focused in pain will be a critical to Analgesic Solutions' ongoing success and rapid expansion going forward

Neurology, Clinical Science

Bryan Yamamoto received his PhD from Syracuse University in Neurobiology after which, he completed a postdoctoral fellowship in clinical pharmacology at the University of Colorado Medical School. He was held at various faculty appointments at the Northeastern Ohio Universities College of Medicine in the Department of Pharmacology, Case Western Reserve University School of Medicine in the Department of Psychiatry, and Boston University School of Medicine in the Department of Pharmacology. He is currently Professor and Chair of the Department of Neurosciences at the University of Toledo College of Medicine and Life Sciences. He has been a member of NIH Study Sections since 1987, an editorial board member of several journals, and a member of several advisory boards of NIH sponsored research centers and programs.

Bryan Yamamoto’s research has focused on how psycho-stimulant drugs including methamphetamine and MDMA (Ecstasy) injure the brain and interact with stress to exacerbate their neuro-toxic effects on neurotransmitter systems and the brain vasculature. He has been funded continuously by the NIH over the last 29 years.

Adi Jaffe received his Ph.D. from the University of California, Los Angeles (UCLA) in 2010. Even before he graduated his name had become known through his online and academic writing. His views on addiction and his research on the topic have been published in dozens of journals and online publications and he has appeared on several television shows and documentaries discussing current topics in addiction and the problem of addiction as a whole. He also teaches courses at UCLA and the California State University in Long Beach that address addiction specifically or biological psychology and behavioral neuroscience more generally. His view is a holistic one, drawing from the best and most recent research to bring as complete a solution to addiction clients. At Alternatives, he serves as the Director of Research, education, and innovation and is in charge of client monitoring, technology solutions, and data collections and outcomes research. His goal is to make Alternatives the best treatment program there is.

His goal is to help push the field of addiction treatment forward to make treatment more accessible and ultimately more successful.

Chris Mc Duffie began Turning Point Addiction Recovery Services several years ago, as an outgrowth of my work with addicted military veterans. Having been a Secondary School Principal & substance abuse counselor for 5+ years, he is specialize in Helping Young Adults ages 12-25, Business Executives & their Employees as well as Parents that need placement assistance for substance abuse, addiction & behavioral health treatment. Over time He became the 'Go-To' leading authority on substance abuse treatment, addiction recovery, drug rehab center consulting, educational consulting and aftercare treatment (especially with Business Executives, Human Resource Directors & their Employees).

For years, He studied everything about drug & alcohol addiction, counseling & treatment, drug rehab centers treatment methodologies, substance abuse treatment, mental health, wellness seminars for Companies, reducing business losses generated by absent, injured, depressed, ill & addicted employees and more.

Elizabeth Halpern is a Psychologist and a Frigate-Commander of the Brazilian Navy, a specialist in Medical Psychology, a Master in Collective Health, and a PhD in Mental Health. She dedicated 28 years in the Brazilian Navy hospitals and outpatient clinics, working as a chief and therapist, from prevention to rehabilitation, giving lectures and courses to military personnel, assisting families, couples, adolescents, and children, in groups and individually. As the Chief of the Center for Chemical Dependency during the last decade, she dedicated her practice towards addiction, and published 14 articles related to drinking practices in the workplace. Presently, she is the Chief of the Health Department of the Central Navy Hospital in Rio de Janeiro, Brazil.

Medical Psychology, Collective Health and Mental Health

Youssef Sari is an Assistant Professor of Pharmacology. He received his Doctorate in Neuroscience from Pierre and Marie Curie University, Institute of Neuroscience, (Paris, France) and subsequently held Post-doc and faculty research positions at Indiana University. He is currently holding a faculty position at the level of Assistant, Professor of Pharmacology at the University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Toledo, Ohio, USA. He is the PI of R01 grant project from NIH-NIAA; the project focuses on the role of glutamate transporter 1 (GLT1) in alcohol-drinking behavior using compounds that upregulate this transporter. He has patents for two compounds that may have potential uses for the treatment of alcohol dependence. He is also testing compounds for the treatment of diseases involving oxidative stress.

His interests are alcohol-drinking behavior and treatment of alcohol dependence